Official Title: “Combining Medications to Enhance Depression Outcomes”

This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind (Subject), Active Control, Parallel Assignment, Efficacy Study

Study Primary Completion Date: September 2009

The overall aim of Combining Medications to Enhance Depression Outcomes (CO-MED) is to enhance remission rates for outpatients with chronic or recurrent nonpsychotic major depressive disorder (MDD) as defined by DSM-IV TR, treated in primary or psychiatric care settings.

Current evidence indicates that remission, the goal of treatment, is found in only about one-third of representative depressed outpatients treated for up to 14 weeks with an initial SSRI. In addition, even for those who do respond or remit, over one-third relapse in the subsequent 12 months. Combinations of antidepressants are used in practice at the second or subsequent steps when relapse occurs in the longer term, or, in some cases, even acutely as a first step when speed of effect is a clinical priority. Whether such combinations could potentially offer higher remission rates, lower attrition, or greater longer-term benefit if used as initial treatments as compared to monotherapy remains to be examined.

CO-MED will test whether two different medications when given in combination as the first treatment step, compared to one medication, will enhance remission rates, increase speed of remission, be tolerable, and provide better sustained benefits in the longer term. Results of this study will inform practitioners in managing the treatment of patients with chronic or recurrent MDD.

Intervention(s) in this Clinical Trial

• Drug: One of the following: bupropion, escitalopram, mirtazapine, or venlafaxine
  • In addition to receiving daily, oral antidepressant medication, participants will also receive daily, oral placebo for up to 28 weeks.
• Drug: Two of the following: bupropion, escitalopram, mirtazapine or venlafaxine
  • Participants will receive daily, oral antidepressant medication combination for up to 28 weeks.

Arms, Groups and Cohorts in this Clinical Trial

• Active Comparator: A
  • Participants will take one antidepressant medication plus placebo.
• Experimental: B
  • Participants will take a combination of two antidepressant medications.

Primary Measures

• Remission rates in patients with chronic and/or recurrent major depression.
  • Time Frame: Measured at Month 7
    Safety Issue?: No

Secondary Measures

• Anxiety, social functioning, quality of life, cognitive and physical well being, treatment emergent psychiatric symptoms, and side-effect burden
  • Time Frame: Measured at Month 7
    Safety Issue?: No

Inclusion Criteria:

• Seeking treatment at the primary or specialty care site, and be planning to continue living in the area of that clinic for the duration of the study
• Meets clinical criteria for nonpsychotic MDD, recurrent (with the current episode being at least 2 months in duration), or chronic (current episode greater than 2 years) as defined by a clinical interview and confirmed by the MINI International
• Neuropsychiatric Interview (MINI)
• Screening 17 item HRSD score of 16 or greater
• Treatment with antidepressant medication combinations is clinically acceptable
• Patient with and without current suicidal ideation may be included in the study as long as outpatient treatment is clinically appropriate

Exclusion Criteria:

• Pregnant or breastfeeding
• Plans to become pregnant over the ensuing 8 months following study entry or are sexually active and not using adequate birth control
• History (lifetime) of psychotic depression, schizophrenia, bipolar (I, II, or NOS), schizoaffective, or other Axis I psychotic disorders
• Current psychotic symptom(s)
• History (within the last 2 years before study entry) of anorexia or bulimia
• Current primary diagnosis of obsessive compulsive disorder
• Current substance dependence that requires inpatient detoxification or inpatient treatment
• Requiring immediate hospitalization for a psychiatric disorder
• Definite history of intolerance or allergy (lifetime) to any protocol medication
• History of clear nonresponse to an adequate trial of an FDA-approved monotherapy in the current MDE if recurrent, or during the last 2 years before study entry if chronic
• History of clear nonresponse to an adequate trial of any study medication used as a monotherapy, or to one or more of the protocol combinations in the current or any prior MDE
• Currently taking any of the study medications at any dose
• Having taken Prozac (fluoxetine) or an MAOI in the 4 weeks before study entry
• Presence of an unstable general medical condition (GMC) that will likely require hospitalization or to be deemed terminal (life expectancy less than 6 months after study entry)
• Currently taking medications or have GMCs that contraindicate any study medications (e.g., seizure disorder)
• Requiring medications for GMCs that contraindicate any study medication
• Epilepsy or other conditions requiring an anticonvulsant
• Lifetime history of having a seizure including febrile or withdrawal seizures
• Receiving or have received vagus nerve stimulation (VNS), electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or other somatic antidepressant treatments
• Currently taking or having taken within the 7 days before study entry any of the following exclusionary medications: antipsychotic medications, anticonvulsant medications, mood stabilizers, or central nervous system stimulants (antidepressant medication used for the treatment of depression or other purposes such as smoking cessation or pain are excluded since these agents may interfere with the testing of the major hypotheses under study)
• Uncontrolled narrow angle glaucoma
• Taking thyroid medication for hypothyroidism may be included only if stable on the medication for 3 months
• Using agents within the 7 days before study entry that are potential augmenting agents (e.g., T3 in the absence of thyroid disease, SAMe, St. John's Wort, lithium, buspirone)
• Therapy that is depression-specific

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 75 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: National Institute of Mental Health (NIMH)

Overall Clinical Trial Officials and Contacts

Madhukar H. Trivedi, MD Principal Investigator University of Texas Southwestern Medical Center  

Overall Contact: Diane Stegman, RN 214-648-4622 diane.stegman@utsouthwestern.edu

Information obtained from ClinicalTrials.gov on November 20, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00590863

Study ID Number: N01 MH90003-02

ClinicalTrials.gov Identifier: NCT00590863

Health Authority: United States: Federal Government